Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: The clinical study titled An Open-label Phase 1 Study to Investigate SGN-CEACAM5C in Adults With Advanced Solid Tumors aims to evaluate the safety and efficacy of the experimental drug PF-08046050 in treating advanced solid tumors. These tumors are challenging to treat due to their size or spread, making this study significant for potential new treatment options.
Intervention/Treatment: The study tests PF-08046050, an antibody-drug conjugate (ADC) designed to target and kill cancer cells. It is administered intravenously, both as a monotherapy and in combination with bevacizumab, another cancer treatment drug.
Study Design: This is an interventional study with a sequential intervention model and no masking. The primary purpose is treatment, focusing on determining the optimal dosage and assessing the safety and efficacy of PF-08046050.
Study Timeline: The study began on November 20, 2023, with primary completion expected in the future. The last update was submitted on August 14, 2025, indicating ongoing progress and adjustments as needed.
Market Implications: This study could influence Sanofi’s stock performance, as positive outcomes may enhance its oncology portfolio. Collaborating with Seagen, a Pfizer subsidiary, positions Sanofi in a competitive stance within the pharmaceutical industry, potentially impacting investor sentiment positively.
The study is ongoing, with further details available on the ClinicalTrials portal.